HomeONCY • NASDAQ
add
Oncolytics Biotech Inc
Previous close
$1.00
Day range
$0.93 - $1.00
Year range
$0.33 - $1.51
Market cap
91.27M USD
Avg Volume
847.89K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (CAD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 13.84M | 39.81% |
Net income | -14.40M | -50.90% |
Net profit margin | — | — |
Earnings per share | -0.14 | -16.67% |
EBITDA | -13.82M | -40.08% |
Effective tax rate | 1.72% | — |
Balance Sheet
Total assets
Total liabilities
| (CAD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 12.35M | -36.97% |
Total assets | 15.06M | -37.94% |
Total liabilities | 14.94M | -1.73% |
Total equity | 115.00K | — |
Shares outstanding | 106.15M | — |
Price to book | ∞ | — |
Return on assets | -197.54% | — |
Return on capital | -872.97% | — |
Cash Flow
Net change in cash
| (CAD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -14.40M | -50.90% |
Cash from operations | -6.65M | -37.64% |
Cash from investing | -7.00K | 78.12% |
Cash from financing | 4.14M | 2,491.91% |
Net change in cash | -2.27M | 56.70% |
Free cash flow | -765.00K | 55.05% |
About
Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that: induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses. Wikipedia
Founded
1998
Headquarters
Website
Employees
28
